Company Overview

Genmab A/S is a Denmark-based biotechnology company focused on the discovery, development, and commercialization of antibody-based therapeutics for cancer and other serious diseases. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on oncology, hematology, and immunology. Genmab’s business model combines proprietary antibody technology platforms, internal drug development programs, and strategic collaborations with major pharmaceutical companies. Revenue is primarily generated through product royalties, collaboration agreements, milestone payments, and licensing arrangements tied to approved and pipeline therapies.

Genmab is best known for its role in developing antibody therapeutics such as Darzalex (daratumumab), developed in partnership with Johnson & Johnson’s Janssen unit, as well as epcoritamab and other investigational oncology therapies. The company has developed proprietary technology platforms including DuoBody, HexaBody, and HexElect, which are designed to enhance antibody functionality and therapeutic effectiveness. Founded in 1999 through the merger of Medarex Europe and Genmab, the company evolved from a research-focused biotechnology enterprise into a commercially significant oncology partner with a growing proprietary pipeline and global development presence.

Business Operations

Genmab operates through a biotechnology business model centered on antibody discovery, clinical development, licensing, and commercialization partnerships. Its core business activities include the advancement of proprietary therapeutic candidates and the monetization of technology platforms through collaborations with pharmaceutical companies. Key operational areas include DuoBody, HexaBody, and antibody-drug conjugate technologies, which support the development of bispecific antibodies and next-generation immunotherapies. Revenue streams are diversified across royalties from marketed products, research funding, milestone payments, and licensing fees.

The company maintains operations across North America, Europe, and Asia, with major commercial and research functions in Denmark, the United States, the Netherlands, and Japan. Genmab collaborates with major pharmaceutical companies including Johnson & Johnson, AbbVie, BioNTech, Seagen, and Novartis on various therapeutic programs. Its operational infrastructure includes clinical development capabilities, translational research operations, and regulatory functions supporting both wholly owned and partnered assets. The company does not operate large-scale manufacturing facilities independently and instead relies on contract manufacturing organizations and strategic production partnerships.

Strategic Position & Investments

Genmab’s strategic direction is focused on expanding its late-stage oncology pipeline while increasing the proportion of wholly owned commercial assets. The company has invested heavily in next-generation antibody technologies and clinical programs targeting hematologic malignancies and solid tumors. Its strategy includes leveraging proprietary antibody engineering platforms to create differentiated therapeutics with enhanced immune activation and tumor-targeting capabilities. Genmab has also prioritized transitioning from a royalty-dependent business model toward broader commercial participation in select therapies.

Major strategic initiatives include the continued development of epcoritamab, acasunlimab, and antibody-drug conjugate programs, as well as collaborations involving artificial intelligence-enabled drug discovery and novel immune-oncology approaches. The company has expanded investments in U.S.-based operations to support global clinical and commercial execution. Genmab’s portfolio strategy combines internal innovation with external partnerships, allowing it to share development risk while retaining long-term economic participation in successful products. Acquisitions have historically been limited compared with larger pharmaceutical peers, with the company favoring partnership-driven growth and platform expansion.

Geographic Footprint

Genmab is headquartered in Copenhagen, Denmark, and maintains a significant operational presence in the United States, particularly in New Jersey and other biotechnology hubs supporting clinical development and commercialization activities. The company also operates in the Netherlands, Japan, and additional international markets through subsidiaries, partnerships, and clinical trial networks. Its therapies and collaborative programs have commercial reach across North America, Europe, and parts of Asia-Pacific.

The company’s global footprint is closely tied to its strategic partnerships with multinational pharmaceutical firms that market Genmab-originated products worldwide. Through these collaborations, Genmab-derived therapies have gained regulatory approvals in numerous international jurisdictions. Its research and development activities are globally integrated, with multinational clinical trials and regulatory engagement across major pharmaceutical markets.

Leadership & Governance

Genmab’s leadership structure combines scientific expertise with commercial and operational experience in biotechnology and oncology therapeutics. The company was co-founded by Jan van de Winkel, who has played a central role in shaping its scientific and strategic direction. Leadership has consistently emphasized long-term innovation, antibody technology leadership, and disciplined capital allocation focused on oncology research and global product development.

Key executives include:

• Jan van de Winkel – President and Chief Executive Officer
• Anthony Pagano – Executive Vice President and Chief Financial Officer
• Judith Klimovsky – Executive Vice President and Chief Development Officer
• Yukiko Yamashita – Executive Vice President and Chief Technical Officer
• Thomas Levin – Executive Vice President and Chief Commercial Officer
• Michael Ryan – Executive Vice President and Chief Legal Officer

Genmab operates under a board-governed corporate structure consistent with Danish corporate governance standards and maintains listings on both the Nasdaq Copenhagen exchange and the Nasdaq Global Select Market in the United States. Leadership strategy has emphasized scientific differentiation, collaborative development, and expansion of proprietary commercial capabilities while maintaining a strong balance sheet and long-term research focus.